Selecta Biosciences, Inc. (SELB) Analysts See $-0.87 EPS

October 13, 2018 - By Linda Rogers

Analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB) to report $-0.87 EPS on November, 6.They anticipate $0.21 EPS change or 31.82 % from last quarter’s $-0.66 EPS. After having $-0.84 EPS previously, Selecta Biosciences, Inc.’s analysts see 3.57 % EPS growth. The stock increased 7.97% or $1.05 during the last trading session, reaching $14.23. About 186,014 shares traded or 56.17% up from the average. Selecta Biosciences, Inc. (NASDAQ:SELB) has declined 19.25% since October 14, 2017 and is downtrending. It has underperformed by 34.87% the S&P500.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company has market cap of $318.70 million. The Company’s lead product candidate is SEL-212, which is in phase I/II clinical trials for the treatment of refractory and chronic tophaceous gout. It currently has negative earnings.

More news for Selecta Biosciences, Inc. (NASDAQ:SELB) were recently published by: Seekingalpha.com, which released: “The Investment Case For Selecta Biosciences” on September 21, 2018. Nasdaq.com‘s article titled: “Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy …” and published on October 05, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>